Grace Therapeutics, Inc. (GRCE) Stock

Grace Therapeutics, Inc. (GRCE) is a Healthcare stock trading at $2.20 (as of 2026-08-21), with a market capitalization of $46.28M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Grace Therapeutics, Inc. develops and commercializes pharmaceutical products for rare and orphan diseases in Canada. Its pipeline includes GTX-104 for subarachnoid hemorrhage, GTX-102 (oral mucosal betamethasone spray) for ataxia-telangiectasia, and GTX-101 (topical bioadhesive film-forming bupivacaine spray) for postherpetic neuralgia; it is headquartered in Princeton, New Jersey.

Understand Grace Therapeutics, Inc.: how it makes money

Grace Therapeutics develops and commercializes pharmaceutical products for rare and orphan diseases in Canada, with its lead pipeline focused on intravenous and other formulations intended to treat specific indications.

The company’s profit model depends on whether its clinical-stage candidates, led by GTx-104, successfully demonstrate clinical benefit and safety in trials, enabling commercialization of pharmaceutical products for rare and orphan diseases.

Business quality (Weak): The company is focused on rare disease drug development and commercialization, with a deeply negative operating margin in the latest provided period (operating margin -1440.6), and no segment revenue breakdown provided in the facts.

Bull case

  • Clinical results for GTx-104 show a lower Clinically Significant Hypotension Incidence (GTx-104) of 28.0 percent versus 35.0 percent for the Oral Nimodipine comparator: This supports the case that GTx-104 may offer an efficacy and tolerability profile relative to the comparator used in the clinical comparison.
  • The STRIVE-ON Safety Trial Enrollment Percentage Surpassed is 50.0 percent, with projected STRIVE-ON Patient Enrollment Percentage of 100.0 percent: This indicates trial enrollment progress toward planned study enrollment.

Bear case

  • Clinically Significant Hypotension Incidence remains 28.0 percent in the GTx-104 arm: Even if improved versus the comparator, a meaningful incidence rate highlights ongoing safety and tolerability risks that can affect development and future commercialization.
  • The latest provided financial snapshot shows operating margin -1440.6 with revenue reported as 0.0B: This suggests significant ongoing losses (at least in the provided period), consistent with the company still operating through development and early commercialization steps rather than generating meaningful product revenue.
Valuation — source: SEC EDGAR (first-party)
Price$2.20
Market Cap$46.28M
Price / Book0.96
Price / Sales67.27
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$685000.00
Net Margin-1137.7%
Revenue Growth (YoY)-3.7%
EPS Growth (YoY)-40.5%
Financial Health — source: SEC EDGAR
Altman Z-Score2.73 (grey)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderCerity Partners LLC ($3.93M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOPrashant Kohli
Employees4
CountryUS
IPO Date2012-02-07

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • TransCode Therapeutics, Inc. (RNAZ)
  • Hyperion DeFi, Inc. (HYPD)
  • Tenax Therapeutics, Inc. (TENX)
  • FILANA THERAPEUTICS, INC. (FLNA)
  • Seres Therapeutics, Inc. (MCRB)
  • Karyopharm Therapeutics Inc. (KPTI)
  • Silo Pharma, Inc. (SILO)
  • Veru Inc. (VERU)
GRCE earnings history · GRCE institutional & insider holders · GRCE KPIs & operating metrics · GRCE financials · GRCE investor presentations & press releases · GRCE SEC filings · GRCE peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.